$CYCC
Cyclacel Pharmaceuticals, Inc.

2021 Form 10-K Financial Statement

#000155837022004769 Filed on March 30, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.461M $1.750M $5.877M
YoY Change 26.95% 28.68% 17.07%
% of Gross Profit
Research & Development $15.48M $1.420M $4.759M
YoY Change 225.22% -0.7% 2.12%
% of Gross Profit
Depreciation & Amortization $43.00K $0.00 $20.00K
YoY Change 115.0% 0.0%
% of Gross Profit
Operating Expenses $22.94M $3.170M $10.64M
YoY Change 115.66% 13.62% 9.88%
Operating Profit -$22.94M -$10.64M
YoY Change 115.66%
Interest Expense $60.00K -$10.00K $60.00K
YoY Change 0.0% -133.33% -81.82%
% of Operating Profit
Other Income/Expense, Net $204.0K $0.00 $955.0K
YoY Change -78.64% -100.0% 315.22%
Pretax Income -$22.73M -$3.180M -$9.681M
YoY Change 134.83% 15.64% 6.04%
Income Tax -$3.847M -$380.0K -$1.236M
% Of Pretax Income
Net Earnings -$18.89M -$2.800M -$8.445M
YoY Change 123.65% 21.21% 7.85%
Net Earnings / Revenue
Basic Earnings Per Share -$2.14 -$3.42
Diluted Earnings Per Share -$2.14 -$771.3K -$3.42
COMMON SHARES
Basic Shares Outstanding 8.926M 3.633M
Diluted Shares Outstanding 8.926M 3.633M

Balance Sheet

Concept 2021 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $36.56M $33.41M $33.41M
YoY Change 9.43% 180.99% 180.99%
Cash & Equivalents $36.56M $33.41M $33.41M
Short-Term Investments
Other Short-Term Assets $656.0K $66.00K $750.0K
YoY Change -12.53% -91.75% -6.25%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $40.94M $35.47M $35.47M
YoY Change 15.43% 152.99% 153.0%
LONG-TERM ASSETS
Property, Plant & Equipment $94.00K $106.0K $1.330M
YoY Change -92.93% -91.78% 3.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.551M
YoY Change
Total Long-Term Assets $1.645M $1.333M $1.330M
YoY Change 23.68% 3.33% 3.1%
TOTAL ASSETS
Total Short-Term Assets $40.94M $35.47M $35.47M
Total Long-Term Assets $1.645M $1.333M $1.330M
Total Assets $42.59M $36.80M $36.80M
YoY Change 15.73% 140.38% 140.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.117M $514.0K $510.0K
YoY Change 315.1% -42.25% -42.7%
Accrued Expenses $2.543M $1.972M $1.110M
YoY Change 129.1% 132.0% 30.59%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.294M $2.486M $2.490M
YoY Change 112.61% 2.73% 2.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $30.00K $1.060M $1.060M
YoY Change -97.17% -10.92% -10.92%
Total Long-Term Liabilities $30.00K $1.060M $1.060M
YoY Change -97.17% -10.92% -10.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.294M $2.486M $2.490M
Total Long-Term Liabilities $30.00K $1.060M $1.060M
Total Liabilities $5.324M $3.543M $3.540M
YoY Change 50.4% -1.86% -1.94%
SHAREHOLDERS EQUITY
Retained Earnings -$366.1M
YoY Change
Common Stock $6.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $37.26M $33.26M $33.26M
YoY Change
Total Liabilities & Shareholders Equity $42.59M $36.80M $36.80M
YoY Change 15.73% 140.38% 140.37%

Cashflow Statement

Concept 2021 2020 Q4 2020
OPERATING ACTIVITIES
Net Income -$18.89M -$2.800M -$8.445M
YoY Change 123.65% 21.21% 7.85%
Depreciation, Depletion And Amortization $43.00K $0.00 $20.00K
YoY Change 115.0% 0.0%
Cash From Operating Activities -$18.54M -$1.150M -$7.934M
YoY Change 133.68% 2.68% -16.04%
INVESTING ACTIVITIES
Capital Expenditures $27.00K -$50.00K $96.00K
YoY Change -71.88% -1060.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities -$27.00K -$50.00K -$96.00K
YoY Change -71.88% -600.0% -420.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.000M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.74M 11.34M 29.50M
YoY Change -26.33% -22780.0% 666.34%
NET CHANGE
Cash From Operating Activities -18.54M -1.150M -7.934M
Cash From Investing Activities -27.00K -50.00K -96.00K
Cash From Financing Activities 21.74M 11.34M 29.50M
Net Change In Cash 3.153M 10.14M 21.52M
YoY Change -85.35% -974.14% -486.37%
FREE CASH FLOW
Cash From Operating Activities -$18.54M -$1.150M -$7.934M
Capital Expenditures $27.00K -$50.00K $96.00K
Free Cash Flow -$18.57M -$1.100M -$8.030M
YoY Change 131.22% -1.79% -14.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.42
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.14
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3633385
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8926173
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6246896
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9993135
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001130166
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Entity Registrant Name
EntityRegistrantName
Cyclacel Pharmaceuticals, Inc.
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3633385
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8926173
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.42
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.14
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-8445000
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
00-50626
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1707622
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Connell Drive
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1500
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Berkeley Heights
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07922
CY2021 dei City Area Code
CityAreaCode
908
CY2021 dei Local Phone Number
LocalPhoneNumber
517-7330
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
54665931
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9993135
CY2021 dei Auditor Firm
AuditorFirmId
49
CY2021 dei Auditor Name
AuditorName
RSM US LLP
CY2021 dei Auditor Location
AuditorLocation
New York, New York
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33406000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36559000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2063000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4383000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
35469000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
40942000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-22938000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
22000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
44000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
42000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
106000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
64000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1227000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
30000
CY2020Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
0
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1551000
CY2020Q4 us-gaap Assets
Assets
36802000
CY2021Q4 us-gaap Assets
Assets
42587000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
514000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2117000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1972000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3177000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2486000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5294000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1057000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30000
CY2020Q4 us-gaap Liabilities
Liabilities
3543000
CY2021Q4 us-gaap Liabilities
Liabilities
5324000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6246896
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9993135
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
400071000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
422960000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-746000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-748000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-366072000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-384959000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
33259000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
37263000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36802000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42587000
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4759000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15477000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5877000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7461000
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
10636000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
22938000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-10636000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-19088000
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.42
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.14
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3633385
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8926173
CY2021 cycc Stock Issued During Period Value At Market Issuance Sales Agreement
StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement
3870000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4565000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1157000
CY2021 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
201000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
16000
CY2020 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
891000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-8445000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-18887000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-7491000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2123000
CY2020 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
7564000
CY2021 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-2125000
CY2021 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-2125000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2123000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-18887000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
37263000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-8445000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-18887000
CY2020 us-gaap Depreciation
Depreciation
20000
CY2021 us-gaap Depreciation
Depreciation
43000
CY2021 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
144000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
955000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
204000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9681000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8372000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18889000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
430000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1157000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22734000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1236000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3847000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-8445000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-18887000
CY2020 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
201000
CY2021 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
201000
CY2020 us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
3775000
CY2021 us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
0
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-12421000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
11697000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
21445000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3775000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4485000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
430000
CY2020 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
201000
CY2020 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
7564000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-7491000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-8445000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
33259000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13502000
CY2020 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-93000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
172000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-124000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3931000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33406000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33406000
CY2020 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
30000
CY2021 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
2906000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7934000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18540000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
96000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
27000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-96000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27000
CY2020 cycc Proceeds From Issuance Of Common Stock And Warrant Exercises Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantExercisesNetOfIssuanceCosts
25160000
CY2021 cycc Proceeds From Issuance Of Common Stock And Warrant Exercises Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantExercisesNetOfIssuanceCosts
17371000
CY2020 us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
4545000
CY2021 us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
4567000
CY2020 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
201000
CY2021 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
201000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29504000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21737000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-17000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
21521000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3153000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11885000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36559000
CY2020 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
42000
CY2021 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
17000
CY2020 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
1291000
CY2021 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
1358000
CY2020 cycc Accrual Of Preferred Stock Dividends
AccrualOfPreferredStockDividends
50000
CY2021 cycc Accrual Of Preferred Stock Dividends
AccrualOfPreferredStockDividends
50000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-18900000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-385000000.0
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36600000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical estimates include inputs used to determine clinical trial accruals and stock-based compensation expense. Cyclacel reviews its estimates on an ongoing basis. The estimates are based on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results may differ from these estimates. Cyclacel believes the judgments and estimates required by the following accounting policies to be significant in the preparation of the Company’s consolidated financial statements.</p>
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36600000
CY2021Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
35900000
CY2021Q4 cycc Cash Financial Services Compensation Scheme Insured Amount
CashFinancialServicesCompensationSchemeInsuredAmount
85000
CY2021Q4 cycc Cash Exceeding Balance Insured By Financial Services Compensation Scheme
CashExceedingBalanceInsuredByFinancialServicesCompensationScheme
330000
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021Q4 us-gaap Number Of Countries In Which Entity Operates
NumberOfCountriesInWhichEntityOperates
2
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2063000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4383000
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1600000
CY2020 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2021 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2020 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2021 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2020Q4 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
1313000
CY2021Q4 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
3727000
CY2020Q4 us-gaap Cash
Cash
28080000
CY2021Q4 us-gaap Cash
Cash
32082000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
5326000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
4477000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33406000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36559000
CY2020Q4 cycc Prepayments And Value Added Tax Receivable Current
PrepaymentsAndValueAddedTaxReceivableCurrent
684000
CY2021Q4 cycc Prepayments And Value Added Tax Receivable Current
PrepaymentsAndValueAddedTaxReceivableCurrent
577000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
66000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
79000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
991000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
425000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
886000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
361000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
106000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
64000
CY2020Q4 cycc Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
781000
CY2021Q4 cycc Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
2310000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
325000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
233000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
866000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
634000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1972000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3177000
CY2020Q3 cycc Lessee Operating Lease Term Of Contract Extension
LesseeOperatingLeaseTermOfContractExtension
P2Y
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
30000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
30000
CY2021 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
752425
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4000000.0
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
430000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1157000
CY2020 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
0
CY2021 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
0
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
2000
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-1238000
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-3849000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-1236000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-428000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-1622000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-9253000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-21112000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9681000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22734000
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
2000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-3847000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1236000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3847000
CY2020Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
1200000
CY2021Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
3800000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9681000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22734000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2033000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4774000
CY2020 cycc Income Tax Reconciliation Nondeductible Expense And Tax Exempt Income
IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome
352000
CY2021 cycc Income Tax Reconciliation Nondeductible Expense And Tax Exempt Income
IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome
328000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
1788000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
4967000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-1238000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-3849000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3205000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
15296000
CY2020 cycc Income Tax Reconciliation Foreign Income Tax Rate Differential And Repatriation Of Foreign Earnings
IncomeTaxReconciliationForeignIncomeTaxRateDifferentialAndRepatriationOfForeignEarnings
1638000
CY2021 cycc Income Tax Reconciliation Foreign Income Tax Rate Differential And Repatriation Of Foreign Earnings
IncomeTaxReconciliationForeignIncomeTaxRateDifferentialAndRepatriationOfForeignEarnings
-177000
CY2020 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-3937000
CY2021 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-12831000
CY2020 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-1011000
CY2021 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-2807000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1236000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3847000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
42012000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
56629000
CY2020Q4 cycc Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Depreciation Amortization And Impairment Losses
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses
39000
CY2021Q4 cycc Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Depreciation Amortization And Impairment Losses
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses
34000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
0
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
67000
CY2020Q4 cycc Deferred Tax Assets Lease Right Of Use Asset
DeferredTaxAssetsLeaseRightOfUseAsset
-183000
CY2021Q4 cycc Deferred Tax Assets Lease Right Of Use Asset
DeferredTaxAssetsLeaseRightOfUseAsset
-32000
CY2020Q4 cycc Deferred Tax Assets Lease Right Of Use Liability
DeferredTaxAssetsLeaseRightOfUseLiability
195000
CY2021Q4 cycc Deferred Tax Assets Lease Right Of Use Liability
DeferredTaxAssetsLeaseRightOfUseLiability
32000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
42063000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
56730000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42063000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
56730000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
56700000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
14700000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-8445000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-18887000
CY2020 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
201000
CY2021 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
201000
CY2020 us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
3775000
CY2021 us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
0
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-12421000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-19088000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3633385
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8926173
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.42
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.14
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5941472
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5529145
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-8445000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-18887000
CY2020Q4 us-gaap Assets
Assets
36802000
CY2021Q4 us-gaap Assets
Assets
42587000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
106000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
64000
CY2021Q4 us-gaap Dividends Payable Date Declared Day Month And Year
DividendsPayableDateDeclaredDayMonthAndYear
2021-12-13

Files In Submission

Name View Source Status
0001558370-22-004769-index-headers.html Edgar Link pending
0001558370-22-004769-index.html Edgar Link pending
0001558370-22-004769.txt Edgar Link pending
0001558370-22-004769-xbrl.zip Edgar Link pending
cycc-20211231.xsd Edgar Link pending
cycc-20211231x10k.htm Edgar Link pending
cycc-20211231x10k_htm.xml Edgar Link completed
cycc-20211231xex23d1.htm Edgar Link pending
cycc-20211231xex31d1.htm Edgar Link pending
cycc-20211231xex31d2.htm Edgar Link pending
cycc-20211231xex32d1.htm Edgar Link pending
cycc-20211231xex32d2.htm Edgar Link pending
cycc-20211231xex4d10.htm Edgar Link pending
cycc-20211231_cal.xml Edgar Link unprocessable
cycc-20211231_def.xml Edgar Link unprocessable
cycc-20211231_lab.xml Edgar Link unprocessable
cycc-20211231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending